- Home
- AMST vs BTAI Comparison
AMST vs BTAI Comparison
Compare AMST & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMST
- BTAI
- Stock Information
- Founded
- AMST 2017
- BTAI 2017
- Country
- AMST United States
- BTAI United States
- Employees
- AMST N/A
- BTAI N/A
- Industry
- AMST Computer Software: Prepackaged Software
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- AMST Technology
- BTAI Health Care
- Exchange
- AMST Nasdaq
- BTAI Nasdaq
- Market Cap
- AMST 9.5M
- BTAI 10.7M
- IPO Year
- AMST 2020
- BTAI 2018
- Fundamental
- Price
- AMST $2.74
- BTAI $1.18
- Analyst Decision
- AMST
- BTAI Buy
- Analyst Count
- AMST 0
- BTAI 5
- Target Price
- AMST N/A
- BTAI $42.60
- AVG Volume (30 Days)
- AMST 3.4M
- BTAI 403.0K
- Earning Date
- AMST 05-15-2025
- BTAI 05-12-2025
- Dividend Yield
- AMST N/A
- BTAI N/A
- EPS Growth
- AMST N/A
- BTAI N/A
- EPS
- AMST N/A
- BTAI N/A
- Revenue
- AMST $82,544.00
- BTAI $1,852,000.00
- Revenue This Year
- AMST N/A
- BTAI $27.23
- Revenue Next Year
- AMST N/A
- BTAI $217.72
- P/E Ratio
- AMST N/A
- BTAI N/A
- Revenue Growth
- AMST N/A
- BTAI 5.47
- 52 Week Low
- AMST $2.00
- BTAI $1.17
- 52 Week High
- AMST $6.27
- BTAI $30.88
- Technical
- Relative Strength Index (RSI)
- AMST 52.51
- BTAI 27.79
- Support Level
- AMST $2.83
- BTAI $1.39
- Resistance Level
- AMST $3.28
- BTAI $1.48
- Average True Range (ATR)
- AMST 0.35
- BTAI 0.11
- MACD
- AMST -0.00
- BTAI -0.01
- Stochastic Oscillator
- AMST 30.44
- BTAI 2.38
About AMST Amesite Inc.
Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.